LY3300054

PD-L1 monoclonal antibody

Networked: 6 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        LY3300054: 6
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        LY3300054: 6
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        LY3300054: 6

Experts

1.	Gandhi, Leena: 4 articles (12/2021 - 01/2021)
2.	Zhao, Yumin: 3 articles (12/2021 - 01/2021)
3.	Szpurka, Anna M: 3 articles (12/2021 - 01/2021)
4.	Xu, Xiaojian: 3 articles (12/2021 - 01/2021)
5.	Yap, Timothy A: 2 articles (12/2021 - 01/2021)
6.	Bang, Yung-Jue: 2 articles (12/2021 - 01/2021)
7.	Carlsen, Michelle: 2 articles (12/2021 - 01/2021)
8.	Chow, Kay Hoong: 2 articles (12/2021 - 01/2021)
9.	Galvao, Violeta R: 2 articles (12/2021 - 01/2021)
10.	Italiano, Antoine: 2 articles (12/2021 - 01/2021)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "High-content molecular analysis of tumor and peripheral tissues from animals treated with LY3300054 reveals distinct adaptive immune activation signatures, and also previously not described modulation of innate immune pathways. " 01/01/2018 - "LY3300054 is shown to induce primary T cell activation in vitro, increase T cell activation in combination with anti-CTLA4 antibody, and to potently enhance anti-tumor alloreactivity in several xenograft mouse tumor models with reconstituted human immune cells. " 12/01/2021 - "This phase Ib trial evaluated safety and antitumor activity of anti-PD-L1 antibody LY3300054 monotherapy or in combination with anti-TIM-3 antibody LY3321367 in patients with MSI-H/dMMR advanced solid tumors. " 01/01/2021 - "A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer." 12/01/2021 - "Eligible patients ≥18 years without prior anti-PD-1/PD-L1 therapy received LY3300054 monotherapy (N = 40) or combination (N = 20); patients with PD-1/PD-L1 inhibitor-resistant/refractory tumors received the combination (N = 22). "
2.	Squamous Cell Neoplasms (Squamous Cell Cancer) 12/15/2021 - "This phase I multicenter study of oral LY3200882 (NCT02937272) comprised dose escalation, monotherapy expansion in grade 4 glioma, and combination therapy in solid tumors (LY3200882 and PD-L1 inhibitor LY3300054), pancreatic cancer (LY3200882, gemcitabine, and nab-paclitaxel), and head and neck squamous cell cancer (LY3200882, cisplatin, and radiation). "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 12/15/2021 - "This phase I multicenter study of oral LY3200882 (NCT02937272) comprised dose escalation, monotherapy expansion in grade 4 glioma, and combination therapy in solid tumors (LY3200882 and PD-L1 inhibitor LY3300054), pancreatic cancer (LY3200882, gemcitabine, and nab-paclitaxel), and head and neck squamous cell cancer (LY3200882, cisplatin, and radiation). "
4.	Ovarian Neoplasms (Ovarian Cancer) 10/01/2021 - "Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors."
5.	Glioma (Gliomas) 12/15/2021 - "This phase I multicenter study of oral LY3200882 (NCT02937272) comprised dose escalation, monotherapy expansion in grade 4 glioma, and combination therapy in solid tumors (LY3200882 and PD-L1 inhibitor LY3300054), pancreatic cancer (LY3200882, gemcitabine, and nab-paclitaxel), and head and neck squamous cell cancer (LY3200882, cisplatin, and radiation). "

Related Drugs and Biologics

1.	B7-H1 Antigen
2.	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)
3.	Phosphotransferases (Kinase)
4.	Ligands
5.	Ramucirumab
6.	merestinib
7.	IDO-1 inhibitor LY3381916
8.	LY3321367
9.	abemaciclib
10.	Immune Checkpoint Inhibitors

Related Therapies and Procedures

1.	Therapeutics